RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Urogen Pharma Stock

Urogen Pharma ROE 2024

Urogen Pharma ROE

1.57

Ticker

URGN

ISIN

IL0011407140

WKN

A2DTCV

In 2024, Urogen Pharma's return on equity (ROE) was 1.57, a 27.68% increase from the 1.23 ROE in the previous year.

Urogen Pharma Aktienanalyse

What does Urogen Pharma do?

Urogen Pharma Ltd is a biopharmaceutical company specializing in the development and marketing of innovative therapies for urological diseases. The company was founded in Israel in 2004 and is headquartered in Ra'anana. Answer: Urogen Pharma Ltd is a biopharmaceutical company specializing in the development and marketing of innovative therapies for urological diseases. Urogen Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Urogen Pharma's Return on Equity (ROE)

Urogen Pharma's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Urogen Pharma's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Urogen Pharma's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Urogen Pharma’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Urogen Pharma stock

What is the ROE (Return on Equity) of Urogen Pharma this year?

The ROE of Urogen Pharma this year is 1.57 undefined.

How has the Return on Equity (ROE) of Urogen Pharma developed compared to the previous year?

The ROE of Urogen Pharma has increased by 27.68% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Urogen Pharma?

A high ROE indicates that Urogen Pharma generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Urogen Pharma?

A low ROE can indicate that Urogen Pharma is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Urogen Pharma affect the company?

A change in ROE (Return on Equity) of Urogen Pharma can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Urogen Pharma?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Urogen Pharma?

Some factors that can influence Urogen Pharma's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Urogen Pharma pay?

Over the past 12 months, Urogen Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Urogen Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Urogen Pharma?

The current dividend yield of Urogen Pharma is .

When does Urogen Pharma pay dividends?

Urogen Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Urogen Pharma?

Urogen Pharma paid dividends every year for the past 0 years.

What is the dividend of Urogen Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Urogen Pharma located?

Urogen Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Urogen Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Urogen Pharma from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.

When did Urogen Pharma pay the last dividend?

The last dividend was paid out on 11/9/2024.

What was the dividend of Urogen Pharma in the year 2023?

In the year 2023, Urogen Pharma distributed 0 USD as dividends.

In which currency does Urogen Pharma pay out the dividend?

The dividends of Urogen Pharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Urogen Pharma

Our stock analysis for Urogen Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Urogen Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.